Highlights
About
Postsurgical Adhesion Prevention
EIO Biomedical is a biotechnology company developing a medical device for the prevention of postsurgical adhesions. The device is designed to issue a sprayable adhesion barrier capable of alleviating problems associated with surgical sewing. The company's proprietary device and bioprocess can convert a single unit of blood plasma for infusion, generating a unique enzymatic combination that actively reduces the adhesion-formation process. A disposable kit is provided with the device to ensure that each patient receives a safe and sterile product. The company has recently initiated a first-in-human clinical trial of their FuseX system for the prevention of surgical adhesions on schedule EIO Biomedical is an NGT3 VC portfolio company.
Identity
| Name | EIO Biomedical |
|---|---|
| Slug | eio-biomedical |
| Type / kind | startup |
| Crunchbase ID | eio-biomedical |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwO20kZ4LDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jan 2023 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Nazareth |
| HQ address | Wadi el-Haj 13, Nazareth, Israel |
Web & social
| https://www.linkedin.com/company/18372599 |
Classifications
Funding
| Total raised | $1.5M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}